PROTEIN POLYMER TECHNOLOGIES SELECTS WILLIAM N. PLAMONDON
III AS NEW CHIEF EXECUTIVE OFFICER
SAN DIEGO,
April 11 -- Protein Polymer Technologies, Inc. (OTC Bulletin
Board: PPTI) announced today the appointment of William
N. Plamondon III as its
new Chief Executive Officer. J. Thomas Parmeter, PPTI's
former CEO, will remain
in his capacity as Chairman of the Board of Directors,
and Donald Kaplan,
Ph.D. will continue as President and Chief Operating Officer.
"Bill Plamondon has been an advisor to PPTI for the last seven months and
was
recently named to the Board of Directors. The addition of Bill to our management
team adds a very broad base of business experience to our capabilities. Over
the course of his career, Bill has served as CEO for several public and
private companies," said J. Thomas Parmeter, PPTI's Chairman. "His
skills and insight will add great value to PPTI's future..." In
his leadership roles, Mr. Plamondon has been the CEO of companies exceeding $3
billion of revenue worldwide. He has successfully driven acquisitions and
reorganizations, in addition to building and growing businesses in a variety
of industries. Bill Plamondon is currently President
and
CEO of R.I. Heller & Co., LLC, a management consulting firm, and serves
on the Board of Directors of several companies, charities and non-profit organizations.
"I look forward to helping a great team of people with outstanding scientific
accomplishments continue to build a great company," Mr. Plamondon
said,
following the announcement of his new role.
Contacts:
J. Thomas Parmeter, Ph.D.
Chairman
Protein Polymer Technologies, Inc.
(858) 558-6064
info@ppti.com
|
|
About
Protein Polymer Technologies
Protein Polymer Technologies,
Inc., is a San Diego-based company focused on developing
bioactive devices to improve
medical and surgical outcomes. From its inception in
1988, PPTI has been a pioneer in protein design and
synthesis, creating an extensive portfolio of proprietary
biomaterials
for use in the development of bioactive devices. These
genetically engineered biomaterials are high molecular
weight proteins, processed into products with physical
and biological characteristics tailored to specific
clinical performance requirements. Targeted products
include urethral
bulking agents for the treatment of stress urinary
incontinence, dermal augmentation products for cosmetic
and reconstructive
surgery, surgical adhesives and sealants, scaffolds
for wound healing and tissue engineering, and depots
for
local drug delivery. To date, PPTI has been issued
twenty-five U.S. Patents on its core technology with
corresponding
issued and pending patents in key international markets.
Safe Harbor
This press release contains forward-looking statements
that are based on management’s views and expectations.
Actual results could differ materially from those expressed
here; further, the Company is not obligated to comment
specifically on those differences. Risks associated with
the Company’s activities include raising adequate
capital to continue operations scientific and product
development uncertainties, competitive products and approaches,
continuing collaborative partnership interest and funding,
regulatory testing and approvals, and manufacturing scale
up. The reader is encouraged to refer to the Company’s
2004
Annual Report Form 10-KSB, and other recent filings
with the Securities and Exchange Commission, copies of
which are available from the Company, to further ascertain
the risks associated with the above statements.
